Skip to content
ClinCalc Pro
Menu
Antibiotic (Macrolide) Pregnancy: Azithromycin should only be used during pregnancy if clinically needed. There are no adequate and well-controlled studies in pregnant women; a large amount of observational data (more than 7000 exposed pregnancies) mostly does not suggest an increased risk of major congenital or cardiovascular malformations, and epidemiological evidence on miscarriage risk after early-pregnancy exposure is inconclusive. Breast-feeding: azithromycin is excreted in human milk to a substantial extent - a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Azithromycin

Brand names: Zithromax

Azithromycin is a macrolide antibiotic used in children for respiratory tract infections, certain atypical and sexually transmitted infections, and pertussis, with a long tissue half-life allowing short courses.

Auto-extracted from the source labelling — not yet independently clinician-verified. These values were distilled from the UK SPC (or the US label where noted) but have not had a clinician sign-off. Confirm against the current SmPC before prescribing.

Adult dose

Dose: Adults and adolescents weighing at least 45 kg who are unable to swallow solid pharmaceutical forms: 500 mg/day for 3 days, or 500 mg on day 1 followed by 250 mg/day on days 2 to 5
Route: Oral suspension after reconstitution - single daily dose, with or without a meal (administration immediately before a meal may enhance gastrointestinal tolerability); shake the bottle before each dose
Frequency: Once daily
Max: Not stated as an absolute maximum for adults in this SPC; the 3-day and 5-day regimens above are the stated adult courses
The fetched SPC is the paediatric-oriented 200 mg/5 ml oral suspension, so its adult posology applies specifically to adults and adolescents weighing at least 45 kg who are unable to swallow solid pharmaceutical forms. Indications covered by the 500 mg/250 mg adult regimen: acute streptococcal tonsillitis and pharyngitis, acute bacterial sinusitis, acute bacterial otitis media, acute exacerbations of chronic bronchitis (adults only), community acquired pneumonia, and acute bacterial skin and skin structure infections. Urethritis and cervicitis caused by Chlamydia trachomatis: 1000 mg as a single dose. For community acquired pneumonia in adults, oral treatment may follow intravenous treatment if clinically indicated to complete a 7 to 10 day total course - refer to the SmPC of the azithromycin IV formulations for that detail. Consideration should be given to the treatment regimens, doses and duration recommended in updated treatment guidelines for each indication. MISSED DOSE: if 12 hours or less have passed, take as soon as possible and take the next dose at the regularly scheduled time; if more than 12 hours have passed, wait until the next scheduled dose. ELDERLY: no dose adjustment required, but particular caution is recommended because the elderly are more likely to experience proarrhythmic conditions (risk of cardiac arrhythmia and torsade de pointes). HEPATIC IMPAIRMENT: no adjustment in mild (Child-Pugh A) or moderate (Child-Pugh B) impairment; no data in severe (Child-Pugh C) - administer with caution.

Paediatric dose

Dose: 10 mg/kg
Route: Oral suspension after reconstitution, as a single daily dose
Frequency: Once daily - 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5
Max: The azithromycin daily dose should not exceed the adult daily dose of 500 mg, with the exception of the 1-day (single dose) course for acute bacterial otitis media, for which the maximum total dose of 1500 mg should not be exceeded. The maximum recommended total dose for any treatment in paediatric patients weighing less than 45 kg is 1500 mg, except for the 5-day regimen for acute streptococcal tonsillitis and pharyngitis.
Applies to paediatric patients aged 6 months and older weighing less than 45 kg. The 10 mg/kg/day figure in dosePerKg is the regimen for ACUTE BACTERIAL SINUSITIS, COMMUNITY ACQUIRED PNEUMONIA and ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS: 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. OTHER INDICATIONS DIFFER: acute bacterial otitis media - a single dose of 30 mg/kg, or 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. Acute streptococcal tonsillitis and pharyngitis - 20 mg/kg/day for 3 days, or 12 mg/kg/day for 5 days. The SPC contains per-weight maximum daily dose tables (Table 2) and suspension volume tables for the 20 mg/ml and 40 mg/ml strengths (Tables 3 and 4) - dispensing volumes must be read from the SPC for the strength being used. There is no relevant use of azithromycin for the treatment of acute exacerbations of chronic bronchitis in paediatric patients. Safety and efficacy have not been established in children under 6 months of age for any indication. Consideration should be given to the treatment regimens, doses and duration recommended in updated treatment guidelines for each indication. Clinician to verify all paediatric doses against a children's formulary before publication.

Dose adjustments

Renal

No dose adjustment is required in patients with GFR of 10 mL/min or above. In patients with GFR below 10 mL/min azithromycin should be administered with caution.

Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.

Paediatric weight-based calculator

Applies to paediatric patients aged 6 months and older weighing less than 45 kg. The 10 mg/kg/day figure in dosePerKg is the regimen for ACUTE BACTERIAL SINUSITIS, COMMUNITY ACQUIRED PNEUMONIA and ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS: 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. OTHER INDICATIONS DIFFER: acute bacterial otitis media - a single dose of 30 mg/kg, or 10 mg/kg/day for 3 days, or 10 mg/kg on day 1 followed by 5 mg/kg/day on days 2 to 5. Acute streptococcal tonsillitis and pharyngitis - 20 mg/kg/day for 3 days, or 12 mg/kg/day for 5 days. The SPC contains per-weight maximum daily dose tables (Table 2) and suspension volume tables for the 20 mg/ml and 40 mg/ml strengths (Tables 3 and 4) - dispensing volumes must be read from the SPC for the strength being used. There is no relevant use of azithromycin for the treatment of acute exacerbations of chronic bronchitis in paediatric patients. Safety and efficacy have not been established in children under 6 months of age for any indication. Consideration should be given to the treatment regimens, doses and duration recommended in updated treatment guidelines for each indication. Clinician to verify all paediatric doses against a children's formulary before publication.

Verify in a children's formulary

Contraindications

  • Hypersensitivity to the active substance, to erythromycin, to any macrolide or ketolide antibiotic, or to any of the excipients

Side effects

  • Diarrhoea (very common)
  • Vomiting, abdominal pain and nausea (common)
  • Headache (common); dizziness (uncommon)
  • Hypersensitivity and angioedema (uncommon); anaphylactic reaction (rare); severe cutaneous adverse reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP
  • QT prolongation, torsade de pointes and arrhythmia including ventricular tachycardia (rare); pseudomembranous colitis; hepatic failure

Interactions

  • Other active substances known to prolong the QT interval - azithromycin should be used with caution in patients receiving these because of the risk of ventricular arrhythmias including torsade de pointes (section 4.4, which cross-refers to section 4.5)
  • NOTE: SPC section 4.5 was not captured in this bundle; the entry above is the interaction stated within section 4.4 - the full interaction section must be checked against the SPC

Clinical monograph

How it works

It binds the bacterial 50S ribosomal subunit and inhibits protein synthesis, giving a bacteriostatic effect against susceptible organisms.

Prescribing in practice

  • Azithromycin prolongs the QT interval, so avoid combining with other QT-prolonging drugs and use caution where there is known cardiac conduction risk.
  • Dose by weight using a children's formulary, and be aware of an association with infantile hypertrophic pyloric stenosis when macrolides are used in very young infants.
  • Gastrointestinal upset is common, and macrolides interact with several drugs metabolised through hepatic enzymes.

Monitoring

Monitor clinical response, gastrointestinal tolerance, and consider cardiac risk where other QT-prolonging factors are present.

Counselling the patient

  • The course is usually short because the medicine stays in the body for some time.
  • Report vomiting, especially forceful vomiting in a young infant.
  • Tell the prescriber about any heart rhythm problems or other regular medicines.

Evidence & guidelines

Azithromycin features in UK guidance for pertussis and selected paediatric infections, with recognised QT-prolongation precautions.

Reference: PHE Antibiotic Guidelines; NICE NG138; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.